Elena Garralda Cabanas

33PUBLICATIONS
445CO-AUTHORS
Molecular targetsLiquid biopsiesAutoimmunityTumour immunologyPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (33)

|Oct 02, 2026
Type II RAF Inhibitor Tovorafenib in Recurrent/Refractory Melanoma or Other Solid Tumors With BRAF Fusions or CRAF/RAF1 Fusions or Amplification: Phase II FIRELIGHT-1 Substudy.

|Sep 29, 2026
Peripheral Blood as the Sole Source for Cancer Neoantigen and Reactive T-Cell Discovery.

|Jul 13, 2026
Application of a Translational Research Platform to Unveil Efficacy Signals and Mechanisms of Resistance of FGFR Inhibitors in Multiple FGFR-Altered Solid Tumors.

|May 23, 2026
Safety and Efficacy of HexaBody-DR5/DR5 in Malignant Solid Tumors: Phase 1/2a Results and Translational Insights Into Observed Hepatotoxicity.

|Apr 07, 2026
A First-in-Human Phase I Clinical Trial Evaluating Clinical Activity and Proof of Mechanism of Tobemstomig, a PD-1-LAG-3 Bispecific Antibody, in Patients with CPI-Experienced Melanoma.

Elena Garralda, Christoph Markert, Victor Moreno

|Dec 16, 2025
Broad Utility of Ultrasensitive Analysis of ctDNA Dynamics across Solid Tumors Treated with Immunotherapy.

Elena Garralda, Charles Abbott, Alma Calahorro

Pageof 6

Frequent Collaborators

8 joint publications

Josep Tabernero

8 joint publications

Emiliano Calvo

7 joint publications

Paolo Nuciforo

7 joint publications

Raquel Perez-Lopez